Search
Amitriptylinoxide
go.drugbank.com/drugs/DB13114ApprovedWithdrawnAmitriptylinoxide has been used in trials studying Major Depression.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeTL-895
go.drugbank.com/drugs/DB16471InvestigationalTL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC50 and a Ki of 1.5 nM and 11.9 nM, respectively. … TL-895 is under investigation in several clinical trials for its safety and efficacy in various conditions: NCT04419623 (completed, COVID-19 in cancer patients), NCT02825836 (active, not recruiting, B
Rifalazil
go.drugbank.com/drugs/DB04934InvestigationalIt is being investigated by ActivBiotics for the treatment of various bacterial infections.
Citraconic acid
go.drugbank.com/drugs/DB04734ExperimentalCitraconic acid is one of the isomeric dicarboxylic acids produced by the distillation of citric acid, or as metabolites by microorganisms, cis-CH3-C(CO2H)=CHCO2H; the trans-isomer is mesaconic acid.
VT-111
go.drugbank.com/drugs/DB05646InvestigationalVT-111 is a 55 kDa secreted glycoprotein belonging to a superfamily of proteins called SERPINS, which share a general structure and mechanism for proteinase inhibition.
Rocatinlimab
go.drugbank.com/drugs/DB18809InvestigationalThe drug works by targeting the OX40 receptor, which plays a role in the immune response associated with atopic dermatitis. … In clinical trials, it has shown significant efficacy and safety compared to a placebo.
AV-COVID-19
go.drugbank.com/drugs/DB15802InvestigationalThe vaccine was developed and tested by Aivita Biomedical, Inc.. As of July 2020, the company is pursuing an adaptive Phase IB-II Randomized Clinical Trial (NCT04386252) to test the vaccine. … The monocytes are then differentiated in vitro into dendritic cells with IL-4 and GM-CSF, incubated with SARS-CoV-2 antigens prior to administration.
DP-VPA
go.drugbank.com/drugs/DB05821InvestigationalDP-VPA is D-Pharm's proprietary lipid modified version of valproic acid (VPA) that demonstrate that DP-VPA is well-tolerated in patients with resistant epilepsy and has a marked effect on reducing seizure
Cediranib
go.drugbank.com/drugs/DB04849InvestigationalThe novel indole-ether quinazoline Cediranib is a highly potent (IC50 < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. It is being developed clinically as a once-daily oral therapy for the treatment o...
Apadenoson
go.drugbank.com/drugs/DB05009InvestigationalIt is developed by Bristol-Myers Squibb and is in phase II of clinical trials.